| Mantry, Parvez |
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy |
|
|
| Terminated | 4 | 6 | US | Placebo, Rifaximin, XIFAXAN® Tablets | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 02/16 | 02/16 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NAVIGATE, NCT04365868: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis |
|
|
| Active, not recruiting | 2b | 357 | Europe, Canada, US, RoW | belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo | Galectin Therapeutics Inc. | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 12/24 | 12/24 | | |
| Recruiting | 2 | 50 | Europe, US | INT-787, Placebo | Intercept Pharmaceuticals | Alcohol Associated Hepatitis | 12/24 | 12/24 | | |
NCT04919642: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma |
|
|
| Completed | 2 | 55 | US | TT-00420 | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration | 02/24 | 02/24 | | |
PACIFIC, NCT05525520: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis |
|
|
| Active, not recruiting | 2 | 58 | Europe, Canada, US, RoW | EP547, Placebo | Escient Pharmaceuticals, Inc | Pruritus | 07/24 | 09/24 | | |
NCT05239468: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC |
|
|
| Active, not recruiting | 2 | 60 | US | Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo | Intercept Pharmaceuticals | Primary Biliary Cholangitis | 11/24 | 02/25 | | |
| Active, not recruiting | 2 | 68 | Europe, US, RoW | Anti-human CCL24 monoclonal antibody (CM-101), Placebo | ChemomAb Ltd. | Primary Sclerosing Cholangitis | 09/24 | 09/25 | | |
VISTAS, NCT04663308: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/25 | 11/25 | | |
FOENIX-CCA4, NCT05727176: Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement |
|
|
| Recruiting | 2 | 120 | Europe, Japan, US, RoW | TAS-120, Futibatinib | Taiho Oncology, Inc. | Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement | 06/25 | 06/26 | | |
| Recruiting | 2 | 246 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline | Nonalcoholic Fatty Liver Disease | 09/25 | 12/25 | | |
NCT06225206: Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients |
|
|
| Recruiting | N/A | 300 | US | donor-derived cell free DNA in liver | Methodist Health System | Liver Transplant Failure | 12/24 | 12/24 | | |
NCT05170854: The Impact of Liver Cirrhosis on Outcomes in Trauma Patients |
|
|
| Completed | N/A | 4774035 | US | | Methodist Health System | Cirrhosis | 09/20 | 09/20 | | |
NCT06225193: Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population |
|
|
| Recruiting | N/A | 300 | US | | Methodist Health System | Fatty Liver | 06/24 | 06/24 | | |
NCT04903548: Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres |
|
|
| Recruiting | N/A | 300 | US | SIRT with Y-90 resin microspheres | Methodist Health System | Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Recruiting | N/A | 30 | US | | Methodist Health System | Alcoholic Hepatitis, Acute Liver Failure | 12/24 | 12/24 | | |
NCT05935800: The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates |
|
|
| Active, not recruiting | N/A | 208 | US | COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC | Methodist Health System | Frailty, Sarcopenia, COVID-19 | 04/24 | 04/24 | | |
NCT06095440: A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center |
|
|
| Recruiting | N/A | 500 | US | Hepatorenal Syndrome outcome in Patients at Methodist Health systems, liver transplantation | Methodist Health System | Hepatorenal Syndrome | 05/24 | 05/24 | | |
DOORwaY90, NCT04736121: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients |
|
|
| Recruiting | N/A | 100 | US | Resin microspheres containing yttrium-90 (Y-90) | Sirtex Medical, Bright Research Partners | Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | 06/24 | 06/25 | | |
| Castillo-Lugo, Jose A |
NCT02602262: Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients |
|
|
| Recruiting | N/A | 125 | US | HIV-infected deceased donor organ | Johns Hopkins University, University of Colorado, Denver, Yale University, Georgetown University, Emory University, Rush University Medical Center, University of Illinois at Chicago, Indiana University, University of Maryland, Columbia University, Icahn School of Medicine at Mount Sinai, Weill Medical College of Cornell University, University of Pittsburgh Medical Center, Methodist Health System, Northwestern University, NYU Langone Health, University of Virginia, Washington University School of Medicine, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infection | 07/25 | 07/26 | | |
| Pagadala, Mangesh |
| Active, not recruiting | 3 | 238 | Europe, Canada, Japan, US, RoW | Linerixibat, Placebo | GlaxoSmithKline | Pruritus | 10/24 | 01/25 | | |
NCT05051293: Comparison of the Concentration of Estrogen and Testosterone Ratio in Male Patients With Cirrhosis and Hypotension |
|
|
| Withdrawn | N/A | 226 | US | serum concentration of estrogen (E1 and E2) and testosterone ratio measurement | Methodist Health System | Hypotension, Cirrhosis | 08/22 | 08/24 | | |
| Araiza, Edgar |
NCT04564625: Relationships Between Vitamin D and Orthopedic Trauma |
|
|
| Active, not recruiting | N/A | 100 | US | Vitamin D Assessment, Fracture | Methodist Health System | Fracture, Fracture Nonunion, Fractures, Bone, Vitamin D | 02/24 | 03/24 | | |
